Abstract
Abstract
Rituximab and hyaluronidase human is a new subcutaneous formulation of rituximab that was recently approved by the US Food and Drug Administration for the treatment of adults with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. With data to support noninferior pharmacokinetics, similar outcomes, and comparable adverse events, rituximab and hyaluronidase human may offer a suitable alternative to intravenous rituximab that could improve convenience for patients and better utilize health-care resources.
